The Gap, Inc. (GAP) research: valuation against peers, fundamentals over time, risk and news coverage
GAP
The Gap, Inc.No data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBEARISHAnalyst Desks Fan Out Across Biotech and Consumer as China Auto Demand Cracks
Sell-side research activity clustered in clinical-stage biotech and consumer discretionary names, with upgrades for ConocoPhillips, SharkNinja, BridgeBio and Cogent offset by reductions at Middleby and Neurogene. The sharper signal came from China, where July passenger vehicle retail sales fell 20% year over year.
- BREAKING STORYBEARISHSell-Side Repositions Consumer and Credit Exposure as Rate Sensitivity Bites
A wave of rating actions reveals a defensive rotation: discretionary retail downgraded, gaming initiated cautiously, and cash-returning names upgraded, against a backdrop of elevated banking risk and constrained BDC earnings growth.
- BREAKING STORYBEARISHSell-Side Turns on U.S. Consumer Discretionary as Barclays Cuts Under Armour and Gap
Barclays downgraded both Under Armour and Gap, pointing to competitive share loss and a promotional environment that threatens gross margin recovery. The moves anchor a broader analyst reshuffle that included a Baird upgrade of First Solar on tariff clarity, a Baird downgrade of Accendra Health, a JPMorgan upgrade of Grupo Cibest on an earnings beat, and fresh Citizens outperform coverage on Securitize.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.